Its deal with AbbVie is a collaboration and option-to-license ... principal accounting officer and treasurer. Don't miss out on Boston-area life science news. Subscribe to the Morning Edition ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...